Disease modifying anti-rheumatic drugs in juvenile idiopathic arthritis: striving for individualized therapy

References

• Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum. 2008;58:15–25.
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–392.
   PubMed Web of Science ®Google Scholar
• Correll CK, Binstadt BA. Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis. Pediatr Res. 2014;75:176–183.
   PubMed Web of Science ®Google Scholar
• Becker ML. Optimization of pediatric rheumatology therapeutics. Clin Pharmacol Ther. 2012;91:597–606.
   PubMed Web of Science ®Google Scholar
• Schaller JG. The history of pediatric rheumatology. Pediatr Res. 2005;58:997–1007.
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–1167.
   PubMed Web of Science ®Google Scholar
• Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses. N Engl J Med. 1960;262:787–794.
   PubMed Web of Science ®Google Scholar
• Funk RS, Brown JT, Abdel-Rahman SM. Pediatric pharmacokinetics: human development and drug disposition. Pediatric Clinics of North America. 2012;59:1001–1016.
   PubMed Web of Science ®Google Scholar
• Kearns GL. Beyond biomarkers: an opportunity to address the ‘pharmacodynamic gap’ in pediatric drug development. Biomark Med. 2010;4:783–786.
   PubMed Web of Science ®Google Scholar
• Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med. 1992;326:1043–1049.
   PubMed Web of Science ®Google Scholar
• Xu Z, Davis HM, Zhou H. Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther. 2013;137:225–247.
   PubMed Web of Science ®Google Scholar
• Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Research. 1983;43:2342–2345.
   PubMed Web of Science ®Google Scholar
• Humira [package insert]. North Chicago, IL: AbbVie Inc.; 2015.
   Google Scholar
• Albers HM, Wessels JA, van der Straaten RJ, et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:46–51.
   PubMed Web of Science ®Google Scholar
• Vilca I, Munitis PG, Pistorio A, et al. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Ann Rheum Dis. 2010;69:1479–1483.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2012–2021.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Ringold S, Bohnsack J, et al. Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. J Rheumatol. 2014;41:2459–2465.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Giannini EH, Spalding SJ, et al. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol. 2014;41:1163–1170.
   PubMed Web of Science ®Google Scholar
• Geikowski T, Becker I, Horneff G, et al. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis. Rheumatology. 2014;53:1245–1249.
   PubMed Web of Science ®Google Scholar
• Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43:1849–1857.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Massa M, Robbioni P, et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34:1158–1163.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Pignatti P, Gerloni V, et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol. 1997;24:1403–1409.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Pignatti P, Massa M, et al. Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis. Clin Exp Rheumatol. 1995;13:779–784.
   PubMed Web of Science ®Google Scholar
• Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201:1479–1486.
   PubMed Web of Science ®Google Scholar
• Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545–555.
   PubMed Web of Science ®Google Scholar
• Hedrich CM, Bruck N, Fiebig B, et al. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Rheumatol Int. 2012;32:3525–3530.
   PubMed Web of Science ®Google Scholar
• Ringold S, Weiss PF, Beukelman T, et al. update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65:2499–2512.
   PubMed Web of Science ®Google Scholar
• Vastert SJ, De Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66(4):1034–1043.
   PubMed Web of Science ®Google Scholar
• Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306:2340–2347.
   PubMed Web of Science ®Google Scholar
• Otten MH, Prince FH, Anink J, et al. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Ann Rheum Dis. 2013;72:721–727.
   PubMed Web of Science ®Google Scholar
• Woerner A, Uettwiller F, Melki I, et al. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open. 2015;1(1):e000036.
   PubMed Web of Science ®Google Scholar
• Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–1288.
   PubMed Web of Science ®Google Scholar
• Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818–825.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–2395.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Di Fuccia G, Molinaro M, et al. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J Rheumatol. 1993;20:1573–1577.
   PubMed Web of Science ®Google Scholar
• Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol. 1999;17:313–320.
   PubMed Web of Science ®Google Scholar
• Dervieux T, Furst D, Lein DO, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004;50:2766–2774.
   PubMed Web of Science ®Google Scholar
• Dervieux T, Furst D, Lein DO, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis. 2005;64:1180–1185.
   PubMed Web of Science ®Google Scholar
• Stamp LK, O’Donnell JL, Chapman PT, et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum. 2010;62:359–368.
   PubMed Web of Science ®Google Scholar
• Stamp LK, Barclay ML, O’Donnell JL, et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011;38:2540–2547.
   PubMed Web of Science ®Google Scholar
• Becker ML, Gaedigk R, van Haandel L, et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum. 2011;63:276–285.
   PubMed Web of Science ®Google Scholar
• Dolezalova P, Krijt J, Chladek J, et al. Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis. Rheumatology. 2005;44:74–79.
   PubMed Web of Science ®Google Scholar
• Calasan MB, den Boer E, de Rotte MC, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. Ann Rheum Dis. 2015;74:402–407.
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552–1563.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096–3106.
   PubMed Web of Science ®Google Scholar
• Skrabl-Baumgartner A, Erwa W, Muntean W, et al. Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response. Scand J Rheumatol. 2015;44:359–362.
   PubMed Web of Science ®Google Scholar
• Ungar B, Haj-Natour O, Kopylov U, et al. Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure. Medicine (Baltimore). 2015;94:e673.
   PubMed Web of Science ®Google Scholar
• Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology. 2014;53:213–222.
   PubMed Web of Science ®Google Scholar
• Goldman JL, Davis HM, Zhou H, et al. Infliximab clearance in children: potential association with resting energy expenditure. Ann Paediatr Rheum. 2012;1:120–125.
   Google Scholar
• Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110–1117.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557–567.
   PubMed Web of Science ®Google Scholar
• Urien S, Bardin C, Bader-Meunier B, et al. Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC Pharmacol Toxicol. 2013;14(1):40.
   PubMed Web of Science ®Google Scholar
• Ward JR. Historical perspective on the use of methotrexate for the treatment of rheumatoid arthritis. J Rheumatol Suppl. 1985;12(Suppl 12):3–6.
   PubMedGoogle Scholar
• Chan ES, Cronstein BN. Methotrexate–how does it really work? Nat Rev Rheumatol. 2010;6:175–178.
   PubMed Web of Science ®Google Scholar
• Funk RS, Van Haandel L, Leeder JS, et al. Folate depletion and increased glutamation in juvenile idiopathic arthritis patients treated with methotrexate. Arthritis Rheumatol. 2014;66(12):3476–3485.
   PubMed Web of Science ®Google Scholar
• De Rotte MC, de Jong PH, Pluijm SM, et al. Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate. Arthritis Rheum. 2013;65:2803–2813.
   PubMed Web of Science ®Google Scholar
• Dhir V, Sandhu A, Kaur J, et al. Comparison of two different folic acid doses with methotrexate–a randomized controlled trial (FOLVARI Study). Arthritis Res Ther. 2015;17(1):156.
   PubMed Web of Science ®Google Scholar
• Nygren-Babol L, Sternesjo A, Jagerstad M, et al. Affinity and rate constants for interactions of bovine folate-binding protein and folate derivatives determined by optical biosensor technology. Effect of stereoselectivity. J Agric Food Chem. 2005;53:5473–5478.
   PubMed Web of Science ®Google Scholar
• Funk RS, Van Haandel L, Becker ML, et al. Low-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line. J Pharmacol Exp Ther. 2013;347:154–163.
   PubMed Web of Science ®Google Scholar
• de Jager W, Hoppenreijs EP, Wulffraat NM, et al. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis. 2007;66:589–598.
   PubMed Web of Science ®Google Scholar
• Spirchez M, Samasca G, Iancu M, et al. Relation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patients. Clin Lab. 2012;58:253–260.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine. 2013;61:345–348.
   PubMed Web of Science ®Google Scholar
• Kaminiarczyk-Pyzalka D, Adamczak K, Mikos H, et al. Proinflammatory cytokines in monitoring the course of disease and effectiveness of treatment with etanercept (ETN) of children with oligo- and polyarticular juvenile idiopathic arthritis (JIA). Clin Lab. 2014;60:1481–1490.
   PubMed Web of Science ®Google Scholar
• Visvanathan S, Wagner C, Marini JC, et al. The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatr Rheumatol Online J. 2010;8:24.
   PubMed Web of Science ®Google Scholar
• Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunology. 1999;163:1521–1528.
   PubMed Web of Science ®Google Scholar
• Uchiyama Y, Yoshida H, Koike N, et al. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int Immunopharmacol. 2008;8:1595–1601.
   PubMed Web of Science ®Google Scholar
• Zhang X, Morcos PN, Saito T, et al. Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Expert Rev Clin Pharmacol. 2013;6:123–137.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Robbioni P, Massa M, et al. Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. Clin Exp Rheumatol. 1992;10:493–498.
   PubMed Web of Science ®Google Scholar
• Frosch M, Strey A, Vogl T, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000;43:628–637.
   PubMed Web of Science ®Google Scholar
• Frosch M, Ahlmann M, Vogl T, et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009;60:883–891.
   PubMed Web of Science ®Google Scholar
• Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. Jama. 2010;303:1266–1273.
   PubMed Web of Science ®Google Scholar
• Holzinger D, Frosch M, Kastrup A, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71:974–980.
   PubMed Web of Science ®Google Scholar
• Moncrieffe H, Ursu S, Holzinger D, et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology. 2013;52:1467–1476.
   PubMed Web of Science ®Google Scholar
• Anink J, Van Suijlekom-Smit LWA, Otten MH, et al. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res Ther. 2015;17(1):200.
   PubMed Web of Science ®Google Scholar
• Klotsche J, Niewerth M, Haas J-P, et al. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2015. doi:10.1136/annrheumdis-annrheumdis-2014-206747. [Epub ahead of print].
   Google Scholar
• Ruemmele FM, Prieur AM, Talbotec C, et al. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis. J Pediatr Gastroenterol Nutr. 2004;39:203–206.
   PubMed Web of Science ®Google Scholar
• Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68:635–641.
   PubMed Web of Science ®Google Scholar
• Van Dijken TD, Vastert SJ, Gerloni VM, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2011;38:1441–1446.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785–796 e783.
   PubMed Web of Science ®Google Scholar
• Katsicas MM, Russo RA. Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab. Clin Rheumatol. 2009;28:985–988.
   PubMed Web of Science ®Google Scholar
• Schmeling H, Minden K, Foeldvari I, et al. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol. 2014;66(9):2580–2589.
   PubMed Web of Science ®Google Scholar
• Mpofu S, Fatima F, Moots RJ. Anti-TNF-alpha therapies: they are all the same (aren’t they?). Rheumatology. 2005;44:271–273.
   PubMed Web of Science ®Google Scholar
• Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301:418–426.
   PubMed Web of Science ®Google Scholar
• Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308–316.
   PubMed Web of Science ®Google Scholar
• Pastore S, Stocco G, Favretto D, et al. Genetic determinants for methotrexate response in juvenile idiopathic arthritis. Front Pharmacol. 2015;6:52.
   PubMed Web of Science ®Google Scholar
• Bulatovic M, Heijstek MW, Van Dijkhuizen EH, et al. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71:1484–1489.
   PubMed Web of Science ®Google Scholar
• De Rotte MC, Bulatovic M, Heijstek MW, et al. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J Rheumatol. 2012;39:2032–2040.
   PubMed Web of Science ®Google Scholar
• Pastore S, Stocco G, Moressa V, et al. 5-Aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis. Rheumatol Int. 2015;35:619–627.
   PubMed Web of Science ®Google Scholar
• Schmeling H, Biber D, Heins S, et al. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J Rheumatol. 2005;32:1832–1836.
   PubMed Web of Science ®Google Scholar
• Hinks A, Moncrieffe H, Martin P, et al. Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Ann Rheum Dis. 2011;70:1395–1400.
   PubMed Web of Science ®Google Scholar
• Cobb J, Cule E, Moncrieffe H, et al. Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases. Pharmacogenomics J. 2014;14:356–364.
   PubMed Web of Science ®Google Scholar
• Moncrieffe H, Hinks A, Ursu S, et al. Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype. Pharmacogenetics and Genomics. 2010;20:665–676.
   PubMed Web of Science ®Google Scholar
• Allantaz F, Chaussabel D, Stichweh D, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med. 2007;204:2131–2144.
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747–754.
   PubMed Web of Science ®Google Scholar
• Jiang K, Sawle AD, Frank MB, et al. Whole blood gene expression profiling predicts therapeutic response at six months in patients with polyarticular juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66(5):1363–1371.
   PubMed Web of Science ®Google Scholar
• Obry A, Lequerré T, Hardouin J, et al. Identification of S100A9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach. Plos One. 2014;9(12):e115800.
   PubMed Web of Science ®Google Scholar
• Obry A, Hardouin J, Lequerre T, et al. Identification of 7 proteins in sera of RA patients with potential to predict ETA/MTX treatment response. Theranostics. 2015;5:1214–1224.
   PubMed Web of Science ®Google Scholar
• Lauridsen MB, Bliddal H, Christensen R, et al. 1H NMR spectroscopy-based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients. J Proteome Res. 2010;9:4545–4553.
   PubMed Web of Science ®Google Scholar
• Madsen RK, Lundstedt T, Gabrielsson J, et al. Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthritis Res Ther. 2011;13(1):R19.
   PubMed Web of Science ®Google Scholar
• Kapoor SR, Filer A, Fitzpatrick MA, et al. Metabolic profiling predicts response to anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65:1448–1456.
   PubMed Web of Science ®Google Scholar
• Young SP, Kapoor SR, Viant MR, et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum. 2013;65:2015–2023.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen Z, Yang S, et al. (1)H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis. Exp Ther Med. 2012;4:165–171.
   PubMed Web of Science ®Google Scholar